Rat pulmonary microvascular endothelial cells (PMVECs, Procell, Wuhan, China) were cultured in complete medium specifically designed for rat PMVECs (CM-R001, Procell) within a humidified incubator set at 5% CO2 and 37 °C. Following enzymatic digestion, PMVECs were harvested and plated into 6-well plates at a density of 1 × 10^5 cells per well. Subsequently, PMVECs were transduced with various lentiviral constructs (VectorBuilder, Guangzhou, China) for a duration of 48 h. To establish an in vitro model of ARDS, PMVECs were exposed to 1 µg/mL LPS for 4 h to induce cellular injury.
Cm r001
Manufactured by Procell
Sourced in China
The CM-R001 is a centrifuge designed for general laboratory use. It features a fixed-angle rotor and can accommodate sample volumes up to 15 mL. The device operates at a maximum speed of 6,000 RPM and generates a maximum relative centrifugal force (RCF) of 4,000 x g. The CM-R001 is intended for applications that require sample separation and concentration.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using cm r001
1
Rat Pulmonary Endothelial Cell ARDS Model
2
Sema3A Modulates Rat PMVEC Damage
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Rat PMVECs (CP-R001) were procured from Procell Life Science & Technology Co., Ltd. (Wuhan, Hubei, China) and cultured in PMVEC-specific complete medium (CM-R001, Procell) at 37 °C with 5% CO 2 . Overexpression plasmid of Sema3A (oe-Sema3A) and the negative control (NC) plasmid were provided by GenePharma Co., Ltd. (Shanghai, China). Well-growing PMVECs were seeded into six-well plates. When the confluence reached around 50%, the cells were transfected with the plasmids using Lipofectamine® 2000 (Thermo Fisher Scientific, Rockford, IL, USA), followed by incubation at 37 °C with 5% CO 2 for 48 h. To induce cell damage, the PMVECs were treated with 1 μg/mL LPS (ST1470, Beyotime Biotechnology Co., Ltd., Shanghai, China) for 4 h. For artificial activation of the ERK/JNK signalling pathways, 4 h after LPS treatment, the cells were treated with 0.1 μM ERK agonist LM22B-10 (HY-104047) or JNK agonist Juglanin (HY-N3442) (both from MedChemExpress, Monmouth Junction, NJ, USA) for 2 h. Overall, the cells were allocated into the following groups: Control (without treatment), LPS, LPS + oe-NC, LPS + oe-Sema3A, LPS+LM22B-10, LPS+LM22B-10+oe-NC, LPS+LM22B-10+oe-Sema3A, LPS+Juglanin, LPS+Juglanin+oe-NC, and LPS+Juglanin+oe-Sema3A.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!